These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11080644)

  • 1. Working at the cutting edge: the creation of allosteric ribozymes.
    Warashina M; Kuwabara T; Taira K
    Structure; 2000 Nov; 8(11):R207-12. PubMed ID: 11080644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity.
    Kuwabara T; Warashina M; Taira K
    Trends Biotechnol; 2000 Nov; 18(11):462-8. PubMed ID: 11058787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Mol Cell; 1998 Nov; 2(5):617-27. PubMed ID: 9844634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosterically controlled single-chained maxizymes with extremely high and specific activity.
    Kuwabara T; Hamada M; Warashina M; Taira K
    Biomacromolecules; 2001; 2(3):788-99. PubMed ID: 11710033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing of the secondary structure of maxizymes.
    Zhou JM; Nakamatsu Y; Kuwabara T; Warashina M; Tanaka Y; Yoshinari K; Taira K
    Nucleic Acids Symp Ser; 1999; (42):219-20. PubMed ID: 10780458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression.
    Hamada M; Kuwabara T; Warashina M; Nakayama A; Taira K
    FEBS Lett; 1999 Nov; 461(1-2):77-85. PubMed ID: 10561500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maxizyme technology.
    Iyo M; Kawasaki H; Taira K
    Methods Mol Biol; 2004; 252():257-65. PubMed ID: 15017055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH; Shore SK; Newkirk TA; Reddy RM; Reddy EP
    Blood; 1995 Apr; 85(8):2162-70. PubMed ID: 7718886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of ribozymes against the bcr-abl mRNAs in vitro.
    James HA; Twomey CM; Mills KI; Gibson I
    Biochem Soc Trans; 1996 Aug; 24(3):409S. PubMed ID: 8878953
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W; Daskalakis M; Finke J; Dölken G
    FEBS Lett; 1994 Jan; 338(2):175-8. PubMed ID: 8307177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
    Kuwabara T; Tanabe T; Warashina M; Xiong KX; Tani K; Taira K; Asano S
    Biomacromolecules; 2001; 2(4):1220-8. PubMed ID: 11777396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosterically controllable maxizymes for molecular gene therapy.
    Iyo M; Kawasaki H; Taira K
    Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH; Shore SK; Reddy EP
    Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression mechanism of the allosteric interactions in a ribozyme catalysis.
    Araki M; Okuno Y; Sugiura Y
    Nucleic Acids Symp Ser; 2000; (44):205-6. PubMed ID: 12903340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
    Lange W; Cantin EM; Finke J; Dölken G
    Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes.
    Wang DY; Lai BH; Sen D
    J Mol Biol; 2002 Apr; 318(1):33-43. PubMed ID: 12054766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavage of an inaccessible site by the maxizyme with two independent binding arms: an alternative approach to the recruitment of RNA helicases.
    Kuwabara T; Warashina M; Taira K
    J Biochem; 2002 Jul; 132(1):149-55. PubMed ID: 12097172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ; Yoon K; Moelling K; Coney LR
    Nucleic Acids Res; 1994 Feb; 22(3):301-7. PubMed ID: 8127665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.